Business Wire

ADVA

22.7.2021 07:02:12 CEST | Business Wire | Press release

Share
ADVA posts record results for Q2 2021

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported record financial results for Q2 2021 ended on June 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005791/en/

Q2 2021 financial summary1

(in thousands of EUR)

Q2

Q2

Change

Q1

Change

 

 

2021

2020

 

2021

 

 

 

 

Revenues

149,354

145,024

3.0%

144,473

3.4%

 

Pro forma gross profit

57,274

50,204

14.1%

55,345

3.5%

 

in % of revenues

38.3%

34.6%

3.7pp

38.3%

0.0pp

 

Pro forma operating income

14,415

10,107

42.6%

12,860

12.1%

 

in % of revenues

9.7%

7.0%

2.7pp

8.9%

0.8pp

 

Operating income (loss)

13,036

8,658

50.6%

11,573

12.6%

 

Net income

12,001

7,629

57.3%

11,228

6.9%

 

 

 

(in thousands of EUR)

Jun. 30

2021

Jun. 30

2020

Change

Mar. 31

2021

Change

 

Cash and cash equivalents

85,023

67,586

25.8%

79,060

7.5%

 

Net cash (+) / Net debt (-)

3,876

-44,928

n.a.

-10,626

n.a.

 

Net working capital

132,767

127,917

3.8%

125,785

5.6%

 

1 Potential difference due to rounding

Q2 2021 IFRS financial results

Revenues in Q2 2021 reached EUR 149.4 million, up by 3.4% from EUR 144.5 million in Q1 2021, also up by 3.0% compared to EUR 145.0 million in Q2 2020. As in the first quarter of the fiscal year, this success was particularly due to high order volume from communication service providers as well as private enterprises and governments.

Pro forma gross profit in Q2 2021 increased by 3.5%, reaching EUR 57.3 million (38.3% of revenues) compared to EUR 55.3 million (38.3% of revenues) in Q1 2021 and increased considerably by 14.1% compared to EUR 50.2 million (34.6% of revenues) reported in Q2 2020. Software and service revenue contribution was strong, and the customer and product mix also supported the gross margin growth.

Pro forma operating income for Q2 2021 was EUR 14.4 million (9.7% of revenues) and increased by 12.1% compared to EUR 12.9 million (8.9% of revenues) reported in Q1 2021. Compared to Q2 2020, pro forma operating income improved significantly by 42.6% from EUR 10.1 million (7.0% of revenues).

Operating income for Q2 2021 of EUR 13.0 million increased by 12.6% from EUR 11.6 million reported for Q1 2021 and significantly increased by 50.6% from EUR 8.7 million in Q2 2020.

Net income reached EUR 12.0 million in Q2 2021, up by 6.9% from EUR 11.2 million in Q1 2021, and significantly up by 57.3% from EUR 7.6 million in Q2 2020.

The company’s cash and cash equivalents totaled EUR 85.0 million, representing an increase of EUR 5.9 million compared to EUR 79.1 million at the end of Q1 2021. Year-over-year cash and cash equivalents substantially increased by EUR 17.4 million from EUR 67.6 million at the end of Q2 2020.

Net cash at the end of Q2 2021 stood at EUR 3.9 million when compared to net debt positions of EUR 10.6 million at the end of Q1 2021 or EUR 44.9 million at the end of Q2 2020, respectively. Thus, Q2 2021 was the first quarter showing a net cash position since the introduction of the accounting standard IFRS 16.

Net working capital at quarter-end was EUR 132.8 million and increased by EUR 7.0 million compared to EUR 125.8 million at the end of Q1 2021.

Management commentary

“We continue to grow our business, showing profits and building our financial resources,” said Brian Protiva, CEO, ADVA. “The macro-environment for our industry continues to be good. The digitization efforts in many global regions are in full swing, and the expansion of communication infrastructure is moving at speed. Security is on the top of our customers’ digital agenda, and we are sharpening our profile as the supplier of choice for trusted network infrastructure. With a record-level order backlog, we will continue to use all of our strengths to produce results that allow us to be a leader in a consolidating market.”

“The second quarter of 2021 marked another record quarter in terms of profitability. While continuing to execute our business transformation strategy, we were able to absorb higher purchase prices of components due to the semiconductor crisis and reached a pro forma EBIT of 9.7%,” commented Uli Dopfer, CFO, ADVA. “Also, cash generation was once again very positive. Despite debt repayments of EUR 7.5 million, we were able to increase cash by EUR 6 million and now report a net cash position of EUR 3.9 million also when applying IFRS 16. With that strong first six months in the bank, I am encouraged that we will manage the current supply bottlenecks and reach for the full year a pro forma EBIT between 7% and 10% of revenues.”

Financial outlook 2021

For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 7.0% and 10.0% of revenues.

The company will publish its financial results for Q3 2021 on October 21, 2021.

Conference call details

ADVA will hold a conference call for analysts and investors today, July 22, 2021, to discuss the Q2 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete half-year report 2021 (January – June) is available as a PDF:

https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye